Axcess Global Sciences & Pruvit v. Vital Health: BHB Ketone Patent Dispute Settled
Axcess Global Sciences and Pruvit Ventures jointly sued Vital Health International in Wyoming federal court over three patents covering BHB-based ketone supplement formulations, targeting the KETOKAFE-BHB product. The case resolved via a confidential settlement and was dismissed with prejudice after 182 days — before the defendant even filed an answer.
Three-patent BHB ketone dispute resolves before defendant responds
On September 23, 2024, Axcess Global Sciences LLC (AGS) and Pruvit Ventures Inc. filed a joint infringement action in the Wyoming District Court against Vital Health International LLC, asserting three U.S. patents — US11020362B2, US10292952B2, and US11241403B2 — covering BHB-based ketone supplement compositions and methods. The accused product was Vital Health’s KETOKAFE-BHB, a commercially available exogenous ketone supplement. The filing of two co-plaintiffs sharing the same patent portfolio is consistent with a licensing or co-ownership arrangement between AGS and Pruvit.
The case closed on March 24, 2025, following a notice of voluntary dismissal with prejudice filed on March 20, 2025. The parties had reached a confidential settlement agreement, and the dismissal was filed pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i) — available because Vital Health had not served an answer, counterclaim, or motion for summary judgment. Critically, the parties jointly requested that the Wyoming court retain jurisdiction to enforce the settlement, which the court granted, preserving a formal enforcement mechanism without requiring re-litigation.
The 182-day resolution — before any substantive defence filing — suggests either swift settlement leverage from a strong multi-patent position or a commercially pragmatic decision by Vital Health to resolve rather than litigate. The public record does not disclose financial terms, licensing conditions, or any product-discontinuation obligations. The court’s retained jurisdiction provision is notably protective for the plaintiffs and signals the settlement contains ongoing obligations worth enforcing.
Filing to Voluntary dismissal in 182 days
182 days — resolved before defendant filed an answer or any substantive motion
Settled and dismissed with prejudice: what the resolution means for both sides
Rule 41(a)(1)(A)(i) dismissal with prejudice after settlement
Because Vital Health never filed an answer, counterclaim, or summary judgment motion, plaintiffs could file a unilateral notice of dismissal under Fed. R. Civ. P. 41(a)(1)(A)(i) — no court order required. Choosing to dismiss with prejudice, rather than without, means plaintiffs permanently relinquished the right to re-sue Vital Health on the same claims. This is a deliberate and binding election, typically made in exchange for meaningful settlement consideration.
Dismissal with prejudiceAGS and Pruvit secure enforceable settlement before any validity challenge
By resolving before Vital Health filed any substantive response, the plaintiffs avoided any invalidity counterclaims or IPR petition risk that a defended litigation might have triggered. The three asserted patents — US11020362B2, US10292952B2, and US11241403B2 — emerge from this case with no adverse judicial finding on validity or infringement. The court’s retained Wyoming jurisdiction further strengthens the plaintiffs’ enforcement position if Vital Health breaches the settlement.
Patents survive unchallengedVital Health exits litigation without admissions but faces ongoing settlement obligations
Vital Health resolved without making any public admissions of infringement or validity, and without incurring the cost of a full trial. However, dismissal with prejudice means it cannot be sued again on the same patent claims for KETOKAFE-BHB. The settlement almost certainly imposes continuing obligations — potentially product modification, royalty payments, or commercialisation restrictions — enforceable in Wyoming federal court. Defendant’s counsel notably never entered a formal appearance.
Ongoing settlement obligations likelyBHB supplement sector put on notice: multi-patent enforcement is viable and fast
The joint enforcement by AGS and Pruvit — combining a patent licensor with a commercial supplement brand — represents a coordinated IP strategy increasingly common in the nutraceutical sector. Competitors marketing exogenous BHB ketone products, particularly coffee-based or MCT-blend formats similar to KETOKAFE-BHB, should treat this outcome as a signal that the AGS/Pruvit patent portfolio is actively enforced and capable of producing rapid, binding resolutions before any validity challenge can be mounted.
Active enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axcess Global Sciences, LLC | Company | BHB ketone supplement IP holders — asserting US11020362B2, US10292952B2, and US11241403B2Search in Eureka ↗ |
| Co-Plaintiff | Pruvit Ventures Inc | Company | Search in Eureka ↗ |
| Defendant | Vital Health International LLC | Company | Vital Health International LLC — maker of the accused KETOKAFE-BHB exogenous ketone productSearch in Eureka ↗ |
| Plaintiff counsel | Alaina Marie Stedillie | Attorney | Counsel for Axcess Global Sciences, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Brian Nelson Platt | Attorney | Counsel for Axcess Global Sciences, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Crowley Fleck PLLPP | Law Firm | Representing Axcess Global Sciences, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Workman Nydegger | Law Firm | Representing Axcess Global Sciences, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Wyoming District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice confirms all three hallmarks of a negotiated exit: a fully executed settlement agreement predating the court filing, a with-prejudice election that permanently bars re-litigation of these specific claims, and an explicit retention of court jurisdiction to enforce continuing obligations. The absence of any answer or counterclaim by Vital Health — and the non-appearance of its counsel — is consistent with a defendant who chose commercial resolution over substantive defence, potentially limiting its exposure on undisclosed settlement terms.
US11020362B2, US10292952B2 & US11241403B2 — BHB Ketone Supplement Formulations
The three asserted patents — US11020362B2, US10292952B2, and US11241403B2 — cover compositions and methods relating to beta-hydroxybutyrate (BHB), the primary exogenous ketone used in commercial ketogenic supplement products. Filed across application numbers US16/720211, US15/454157, and US17/198634 respectively, they represent a layered patent family protecting different aspects of BHB formulation, delivery, and use. BHB supplements have grown into a multi-hundred-million-dollar category, making these patents commercially significant assets in the nutraceutical space.
For competitors in the exogenous ketone market — particularly brands formulating BHB salts into coffee blends, ready-to-drink formats, or powder supplements similar to the accused KETOKAFE-BHB — this patent family represents a material IP risk. AGS, as the apparent licensor, has demonstrated willingness to enforce jointly with a downstream commercial partner (Pruvit), a structure that increases litigation efficiency and settlement leverage. Any company with a BHB-forward product line should assess claim overlap with all three patents before expanding into new SKUs or distribution channels.
Should your BHB supplement product be cleared against US11020362B2 and its family?
R&D and product teams developing exogenous ketone supplements — particularly those using BHB salts in coffee, MCT, or powder formats — should treat this three-patent family as a primary FTO target. The KETOKAFE-BHB enforcement demonstrates that AGS and Pruvit are actively monitoring the competitive landscape and willing to act pre-emptively. A freedom-to-operate analysis covering all three patent numbers and their claim scope is advisable before product launch or significant market expansion.
PatSnap Eureka’s FTO Search Agent enables IP and R&D teams to map claim language across US11020362B2, US10292952B2, and US11241403B2 against your specific formulation parameters in minutes. Eureka identifies overlapping claim elements, flags continuation risk from related applications in the AGS/Pruvit portfolio, and surfaces prior art that could support design-around strategies — providing the analytical foundation your counsel needs to clear or differentiate your BHB product confidently.
Run a freedom-to-operate analysis on US11020362B2 to assess your product’s exposure
Run FTO in Eureka →Similar BHB ketone supplement patent infringement cases in U.S. federal courts
Explore related exogenous ketone and BHB supplement patent disputes filed in U.S. district courts, including cases involving AGS, Pruvit, and competing nutraceutical brands.
What this case signals for the BHB ketone supplement IP landscape
A pre-answer settlement across three patents shows coordinated enforcement is working — and that the ketone supplement patent thicket is real.
No validity ruling means all three patents remain fully enforceable
Because Vital Health never filed a counterclaim or IPR petition, US11020362B2, US10292952B2, and US11241403B2 emerged from this case without any judicial or PTAB scrutiny. Competitors cannot rely on this case as precedent for invalidity arguments. Each patent retains full presumptive validity and can be asserted independently in future enforcement actions.
Court-retained jurisdiction is an enforcement tool competitors should note
The plaintiffs’ request — and the court’s agreement — to retain Wyoming jurisdiction over the settlement is a sophisticated enforcement move. Any breach by Vital Health triggers contempt or breach-of-contract proceedings without requiring a new lawsuit. This structure is increasingly used by patent holders in nutraceutical licensing disputes to maintain commercial leverage post-resolution.
Axcess v Vital — key questions answered
Three patents were asserted: US11020362B2, US10292952B2, and US11241403B2. All relate to BHB-based exogenous ketone supplement formulations and were filed under application numbers US16/720211, US15/454157, and US17/198634 respectively. The accused product was Vital Health’s KETOKAFE-BHB supplement.
The case was resolved via a confidential settlement agreement and voluntarily dismissed with prejudice on March 20, 2025, under Fed. R. Civ. P. 41(a)(1)(A)(i). Vital Health never filed an answer or counterclaim. The court retained jurisdiction in Wyoming to enforce the settlement terms at the parties’ joint request.
The public record does not disclose the precise ownership or licensing arrangement between AGS and Pruvit. However, joint filing by both entities is consistent with either co-ownership of the asserted patents or an exclusive licensing structure requiring both parties to have standing. This co-plaintiff model also concentrates enforcement resources and can increase settlement pressure on a defendant.
Dismissal with prejudice permanently bars AGS and Pruvit from re-suing Vital Health on the same patent claims for the KETOKAFE-BHB product. However, the three asserted patents remain valid and enforceable against all other parties. The court’s retained jurisdiction allows plaintiffs to enforce the settlement agreement itself — distinct from re-litigating the original infringement claims.
No. Because Vital Health did not file any invalidity counterclaims, IPR petitions, or substantive motions, there is no adverse judicial finding on validity or infringement scope. All three patents retain their full presumptive validity under 35 U.S.C. § 282 and can be asserted independently against other parties in future enforcement actions.
PatSnap Eureka searches patents and litigation data to answer instantly.